News | April 14, 2026
Briefs: Indoco Remedies and Panacea Biotec
Panacea Biotec receives LoA from CMSS
Panacea Biotec receives LoA from CMSS
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
A brand from Opella will be part of the official NASA astronaut formulary
Highlights Mirvetuximab-based regimen promise
The campaign builds on the three-year partnership unveiled earlier this season
The license is valid for five years, effective from April 9, 2026
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
Subscribe To Our Newsletter & Stay Updated
